Back to Stocks
Stock detail
Alnylam Pharmaceuticals, Inc.
ALNYSTOCKS | US | NASDAQ | Healthcare | Biotechnology
Profile snapshotUSD 288.4Market cap USD 38.5B
No local candle data found.
Recent detected patterns / setups
Latest 10 Market Radar results for this symbol.
PatternTFDetectedQuality
BearishOrder Block Setup15M28 Jul 26, 15:4579
BullishFVG Reaction Setup15M + 15M28 Jul 26, 15:4587
BullishOrder Block Setup4H28 Jul 26, 13:3063
BullishMA 8/21 Crossover4H28 Jul 26, 13:3077
BullishOliver Kell Momentum Setup4H28 Jul 26, 13:3079
BullishFVG Reaction Setup4H + 15M28 Jul 26, 15:4585
BearishMA 21/55 Crossover1D28 Jul 26, 00:0086
BullishTriple Bottom15M28 Jul 26, 15:4571
Annual
Annual fundamentals
2025 vs previous annual period
Metric202020212022202320242025
Total revenueUSD 492.9M+124.3%USD 844.3M+71.3%USD 1B+22.9%USD 1.8B+76.2%USD 2.2B+23.0%USD 3.7B+65.2%
Net incomeUSD -858.3M+3.1%USD -852.8M+0.6%USD -1.1B-32.6%USD -440.2M+61.1%USD -278.2M+36.8%USD 313.7M+212.8%
Net profit margin-174.1%+56.8%-101.0%+42.0%-109.0%-7.9%-24.1%+77.9%-12.4%+48.6%8.4%+168.3%
EPS-7.46+8.0%-7.2+3.5%-9.3-29.2%-3.52+62.2%-2.18+38.1%2.39+209.6%
Quarterly
Quarterly fundamentals
Q1 2026 vs same quarter previous year
MetricQ4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Total revenueUSD 593.2M+34.9%USD 594.2M+20.2%USD 773.7M+17.3%USD 1.2B+149.3%USD 1.1B+84.9%USD 1.2B+96.4%
Net incomeUSD -83.8M+39.2%USD -57.5M+12.8%USD -66.3M-292.4%USD 251.1M+325.0%USD 186.4M+322.6%USD 206M+458.4%
Net profit margin-14.1%+55.0%-9.7%+27.5%-8.6%-234.7%20.1%+190.3%17.0%+220.3%17.6%+282.4%
EPS-0.65+40.9%-0.44+15.4%-0.51-292.3%1.91+319.5%1.41+316.9%1.55+452.3%
Ownership
Institutional ownership summary
2026 Q2, quarter ended 2026-06-30
PeriodOwnershipInstitutions13F sharesTotal investedPositionsPut/call
2026 Q22026-06-30